DAY
6-8
6-8
Aspergillus detected, Liposomal Amphotericin B
was initiated.*
was initiated.*
*Please refer to the Summary of Product Characteristics of your chosen treatment prior to prescribing.
**Administration of a test dose is advisable before a new course of Liposomal Amphotericin B treatment.
Therapy is usually started at a daily dose of 1.0 mg/kg and increased stepwise to 3.0 mg/kg, as required.7
**Administration of a test dose is advisable before a new course of Liposomal Amphotericin B treatment.
Therapy is usually started at a daily dose of 1.0 mg/kg and increased stepwise to 3.0 mg/kg, as required.7
Hamza's bronchoscopy showed endobronchial
lesions indicative of tracheobronchitis.
lesions indicative of tracheobronchitis.
Bronchoalveolar lavage (BAL) samples were
sent for galactomannan determination and
culture. Hamza's sample was positive for
galactomannan and culture was positive for
Aspergillus spp., confirming the diagnosis of
influenza-associated pulmonary aspergillosis.
sent for galactomannan determination and
culture. Hamza's sample was positive for
galactomannan and culture was positive for
Aspergillus spp., confirming the diagnosis of
influenza-associated pulmonary aspergillosis.
Based on the high mortality associated with
Aspergillus tracheobronchitis , Hamza was
started on treatment with Liposomal
Amphotericin B (3 mg/kg)** immediately after
his bronchoscopy.
Aspergillus tracheobronchitis , Hamza was
started on treatment with Liposomal
Amphotericin B (3 mg/kg)** immediately after
his bronchoscopy.
Decision point
Why Liposomal Amphotericin B
